Nerviano Medical Sciences SRL
https://www.nervianoms.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nerviano Medical Sciences SRL
Deal Watch: Coherus Terminates Immuno-Oncology Alliance With Junshi
Plus deals involving Menarini/VenatoRx, Orion/Glykos, Roche/MOMA, Janssen/Elektrofi, Galapagos/BridGene along with 13 other transactions.
Deal Watch: GSK Gets Rights To Spero’s Phase III Antibiotic
GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.
IPO Update: Returns Sag As Seven More Biopharmas Go Public In September
The average return for the 54 drug developers that went public in the US during first three quarters of 2018 was 13.6% as of Oct. 1 versus 16.9% as of Aug. 31 for the 47 biopharma firms that launched IPOs during the first eight months of this year. September had seven new offerings after just two in August.
Biopharma Quarterly Deal-making Statistics, Q4 2017
Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS' massive $77 billion acquisition of Aetna resulted in an all-time quarterly high in the M&A category, and the largest alliances were dominated by the development of vaccines and antibodies.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice